Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00309660
Status:
UNKNOWN
Last Update Posted:
2006-09-21
First Post:
2006-03-30
Brief Title:
Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
Sponsor:
Herlev Hospital
Organization:
Herlev Hospital
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2006-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand rosiglitazone in distal ulcerative colitisThe patients are treated with rosiglitazone enema once a day for fourteen days Disease activity was assessed before and after treatment by endoscopical and clinical activity score
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None